Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GOVXW 
GeoVax Labs Inc (GOVXW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: GOVXW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -21.43% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 3.44 | 52 Weeks Range 0.01 - 0.65 | Updated Date 06/28/2025 |
52 Weeks Range 0.01 - 0.65 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -330.18% |
Management Effectiveness
Return on Assets (TTM) -915.19% | Return on Equity (TTM) -78814.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 13761977 |
Shares Outstanding - | Shares Floating 13761977 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
GeoVax Labs Inc
Company Overview
History and Background
GeoVax Labs Inc. was founded in 2001. It focuses on developing immunotherapies and vaccines using its MVA-VLP platform technology. It has evolved from early research to clinical trials for various infectious diseases and cancers.
Core Business Areas
- Vaccine Development: Focuses on developing vaccines for infectious diseases like HIV, Ebola, Zika, and Lassa fever.
- Immunotherapy Development: Develops immunotherapies for cancer, including solid tumors.
- Licensing and Partnerships: Generates revenue through licensing its technology and partnering with other companies and organizations.
Leadership and Structure
David Dodd is the President and CEO. The company has a board of directors and operates with a typical corporate structure for a biotech company.
Top Products and Market Share
Key Offerings
- GEO-CM04S1 (COVID-19 Vaccine): A modified vaccinia Ankara (MVA) vector-based vaccine designed to elicit antibody and T cell responses against SARS-CoV-2. It is undergoing clinical trials. Market share is currently negligible as it is still in development. Competitors include Pfizer (PFE), Moderna (MRNA), and Novavax (NVAX).
- GEO-HM02 (HIV Vaccine): An MVA-VLP vaccine for HIV prevention. It is also in clinical trials. Market share is negligible as it is still in development. Competitors include Gilead Sciences (GILD) and Janssen (JNJ) although these are treatments not preventive vaccines.
- Gedeptinu00ae: A gene-directed enzyme prodrug therapy (GDEPT) currently in clinical development stage for cancer treatment, specifically, solid tumors. It is in clinical trials, with market share that is currently negligible. Competitors include many large pharmaceutical companies such as Merck (MRK) and Bristol Myers Squibb (BMY).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high risk, high reward, and lengthy development timelines. It is influenced by regulatory approvals, clinical trial outcomes, and competitive pressures.
Positioning
GeoVax Labs Inc. is a small-cap biotech company focused on innovative vaccine and immunotherapy development. Its competitive advantage lies in its MVA-VLP platform, which it believes can induce strong and durable immune responses.
Total Addressable Market (TAM)
The total addressable market varies depending on the specific vaccine or immunotherapy target. The global vaccine market is projected to reach hundreds of billions of USD. GeoVax is positioned to capture a portion of this TAM through successful clinical trials and commercialization.
Upturn SWOT Analysis
Strengths
- Proprietary MVA-VLP vaccine platform
- Experienced leadership team
- Diversified pipeline of vaccine and immunotherapy candidates
- Strong pre-clinical data
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Competition from larger pharmaceutical companies
- Lack of commercialized products
Opportunities
- Partnerships with larger pharmaceutical companies
- Government funding for vaccine development
- Expanding pipeline into new disease areas
- Positive clinical trial results
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established vaccines and therapies
- Economic downturn affecting investment in biotechnology
Competitors and Market Share
Key Competitors
- PFE
- MRNA
- NVAX
- GILD
- JNJ
- MRK
- BMY
Competitive Landscape
GeoVax Labs Inc. faces intense competition from larger, more established pharmaceutical companies with greater resources. Its success depends on its ability to differentiate its MVA-VLP platform and achieve positive clinical trial outcomes. While they might have innovative approach, they lack financial muscle.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by periods of high volatility related to clinical trial announcements.
Future Projections: Future growth projections are highly speculative and dependent on successful clinical trials and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing COVID-19 vaccine trials, exploring partnerships for cancer immunotherapy, and securing government funding.
Summary
GeoVax Labs Inc. is a small biotech company with a promising MVA-VLP platform technology, but faces significant challenges. Their innovative approach and diversified pipeline of vaccine and immunotherapy candidates are their major strengths. The company's success is heavily reliant on positive clinical trial results and securing adequate funding, and the intense competition in the pharmaceutical industry poses a continuous threat to success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GeoVax Labs Inc
Exchange NASDAQ | Headquaters Smyrna, GA, United States | ||
IPO Launch date 2020-09-25 | Chairman, President & CEO Mr. David Alan Dodd | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://www.geovax.com |
Full time employees 17 | Website https://www.geovax.com | ||
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.